Expectations trend
FY2028 · fiscal year ending 2028-03-31 · fmp
Vistagen Therapeutics Inc (VTGN)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.19+11.49%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for VTGN yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Compliance with Nasdaq Listing Rule 5605(c)(2) | A supporting condition in Vistagen Therapeutics Inc's published investment case. The stated target is Resolve audit committee issues and maintain Nasdaq listing. | Under Pressure | Failure to regain Nasdaq compliance or delisting occurs | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-03-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 12, 2026
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk clinical-development story, not an established earnings compounder. The thesis is currently intact, but evidence is mixed: clinical work is on track while financial runway and Nasdaq compliance remain concerns.
The evidence describes VTGN as cheap versus peers, but confidence in that comparison is low. The snapshot does not specify what investors expect from upcoming study results, so the expectations gap is unclear.
Near term, VTGN is likely to remain loss-making as it funds clinical development; R&D expense was elevated, and cash declined to $31.7 million by 2027-Q1. Management has continued advancing fasedienol studies, but runway extension is mixed, a recent earnings miss adds risk, and Nasdaq compliance remains unresolved.
The multi-year view hinges on progress in the Phase 3 and Phase 2 studies, expected topline results in 2026, and the planned FDA engagement on a registrational path. Near term, another guidance cut or continued cash use could weaken the thesis, while broader Healthcare-sector strength is a possible support but does not resolve company-specific risks.
Over the next 1 to 3 years, VTGN’s case depends on clinical progress translating into a clearer path forward before limited runway and compliance risks become more pressing. The evidence is mixed, and the valuation comparison has low confidence. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Vistagen is testing a new drug in a big Phase 3 trial. |
| Improving |
| Trial results are negative or delayed beyond Q2 2026 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Effective workforce reduction to manage cash and prioritize trials | The company cut its workforce by 20% to save cash. | Under Pressure | Cash burn increases or workforce reduction reversed | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.54 → $-1.54 · observed estimates
$0.00B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-1.54 | $0 | 1 / 1 |
| 2026-07-25 | $-1.54 | $0 | 1 / 1 |
| 2026-07-26 | $-1.54 | $0 | 1 / 1 |
| 2026-07-27 | $-1.54 | $0 | 1 / 1 |
| 2026-07-28 | $-1.54 | $0 | 1 / 1 |
| 2026-07-29 | $-1.53 | $7,000,000 | 1 / 1 |
| 2026-07-30 | $-1.53 | $7,000,000 | 1 / 1 |
| 2026-07-31 | $-1.53 | $7,000,000 | 1 / 1 |
| 2026-08-01 | $-1.53 | $7,000,000 | 1 / 1 |
| 2026-08-02 | $-1.53 | $7,000,000 | 1 / 1 |
| 2026-08-03 | $-1.53 | $7,000,000 | 1 / 1 |
| 2026-08-04 | $-1.53 | $7,000,000 | 1 / 1 |
| 2026-08-05 | $-1.53 | $7,000,000 | 1 / 1 |
| 2026-08-06 | $-1.53 | $7,000,000 | 1 / 1 |
| 2026-08-08 | $-1.53 | $7,000,000 | 1 / 1 |
| 2026-08-09 | $-1.53 | $7,000,000 | 1 / 1 |
| 2026-08-10 | $-1.54 | $0 | 1 / 1 |
| 2026-08-12 | $-1.53 | $7,000,000 | 1 / 1 |
| 2026-08-13 | $-1.54 | $0 | 1 / 1 |
| 2026-08-14 | $-1.53 | $7,000,000 | 1 / 1 |
| 2026-08-15 | $-1.53 | $7,000,000 | 1 / 1 |
| 2026-08-16 | $-1.53 | $7,000,000 | 1 / 1 |
| 2026-08-17 | $-1.53 | $7,000,000 | 1 / 1 |
| 2026-08-18 | $-1.53 | $7,000,000 | 1 / 1 |
| 2026-08-19 | $-1.53 | $7,000,000 | 1 / 1 |
| 2026-08-20 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-08-21 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-08-22 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-08-23 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-08-24 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-08-25 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-08-26 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-08-27 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-08-28 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-08-29 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-08-30 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-08-31 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-09-01 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-09-02 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-09-03 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-09-04 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-09-05 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-09-06 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-09-07 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-09-08 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-09-09 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-09-10 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-09-11 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-09-12 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-09-13 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-09-14 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-09-15 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-09-16 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-09-17 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-09-18 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-09-19 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-09-20 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-09-21 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-09-22 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-09-23 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-09-24 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-09-25 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-09-26 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-09-27 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-09-28 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-09-29 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-09-30 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-10-01 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-10-02 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-10-03 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-10-04 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-10-05 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-10-06 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-10-07 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-10-08 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-10-09 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-10-10 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-10-11 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-10-12 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-10-13 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-10-14 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-10-15 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-10-16 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-10-17 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-10-18 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-10-19 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-10-20 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-10-21 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-10-22 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-10-23 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-10-24 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-10-25 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-10-26 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-10-27 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-10-28 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-10-29 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-10-30 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-10-31 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-11-01 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-11-02 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-11-03 | $-1.54 | $7,000,000 | 1 / 1 |
| 2026-11-04 | $-1.54 | $7,000,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 0 Buy / Strong Buy · 4 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.